The Swiss government signs a deal to reserve 8,640 doses of the Merck & Co. antiviral drug molnupiravir, with the said drug should be available at least January 2022.
The Swiss government signs a deal to reserve 8,640 doses of Merck & Co.'s antiviral drug molnupiravir beginning in January.